Global Cancer Gene Therapy Market, By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), End User (Hospitals, Oncology Institutes, Biotechnological Companies, Clinical Research Laboratories) – Industry Trends and Forecast to 2029.
Cancer Gene Therapy Market Analysis and Size
According to the World Health Organization, the second-leading cause of death worldwide in 2018, cancer claimed approximately 9.6 million lives. About 1 in 6 fatalities worldwide are caused by cancer. The global market for cancer gene therapy is expanding vigorously as a result of this market situation. Additionally, rising R&D investments, rising demand for DNA vaccines, improving regulatory standards regarding the quality of products used in gene therapy, and ethical acceptance of gene therapy treatments for cancer are the factors anticipated to propel growth of the global cancer gene therapy market over the course of the forecast period.
Data Bridge Market Research analyses that the cancer gene therapy market which was USD 1.73 billion in 2021, would rocket up to USD 3.63 billion by 2029, and is expected to undergo a CAGR of 9.70% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Cancer Gene Therapy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), End User (Hospitals, Oncology Institutes, Biotechnological Companies, Clinical Research Laboratories)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Biogen (U.S.), Sarepta Therapeutics Inc. (U.S.), Gilead Sciences, Inc. (U.S.), Amgen, Inc. (U.S.), Novartis AG (Switzerland), Orchard Therapeutics Plc (U.K.), Spark Therapeutics, Inc. (U.S.), AGC Biologics (U.S.), Anges, Inc. (Japan), Bluebird Bio, Inc. (U.S.), Jazz Pharmaceuticals Inc. (Ireland), Dynavax Technologies (U.S.), Human Stem Cells Institute (Russia), Sibiono (China), Shanghai Sunway Biotech Co., Ltd. (China), Uniqure N.V. (Netherlands), Gensight Biologics (France), Celgene Corporation (U.S.), Cellectis (France)
|
|
Market Opportunities
|
|
Market Definition
Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians. Gene therapy has quickly gained popularity as a novel method for treating human ailments. The significant developments in the domains of cancer biology, molecular biology, immunology, molecular genetics, and virology have led to the development of cancer gene therapy. Gene therapy strategies for treating cancer are frequently intended to supplement already-effective treatments like chemotherapy and immunotherapy. In other cases, gene therapy has given researchers the means to take advantage of recently discovered knowledge on the function of oncogenes and tumour suppressor genes.
Cancer Gene Therapy Market Dynamics
Drivers
- Improving regulatory scenario has surged the cancer gene therapy market
In the forecast period, an improved regulatory environment will accelerate the expansion of the cancer gene therapy business. Due to their direct connection to consumer health, regulations are placed on producers to assure the release of products (vectors) that are free from flaws. Laws have been changed to prevent product recalls during post-marketing surveillance since any flaws in gene therapy goods could be disastrous for patients. Therefore, the expansion of the cancer gene therapy market in the years to come will be aided by the growing availability of high-quality cancer gene therapy.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of cancer gene therapy market is the upsurge in R&D activities and advancement in product technologies and new product launches by the key players, is leading the healthcare infrastructure to new heights. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding, which will further influence the market dynamics.
- Rise in the geriatric population
The rising prevalence rates of lifestyle disorders like as diabetes and obesity, rising health-care spending, and the fast-growing diagnostic industry are driving the worldwide cancer gene therapy market expansion. In addition, the growing elderly population, increased demand for laboratory automation, and more awareness of preventative healthcare are all driving the cancer gene therapy market forward.
Opportunities
- Increase in the number of research and development activities
The cancer gene therapy market's growth is fuelled by an increase in funding of research and development in the activities of cancer gene therapy along with rise in prevalence of cancer. This will provide beneficial opportunities for the market growth.
Moreover, increasing emerging markets and new product launches will further provide beneficial opportunities for the market growth during the forecast period.
Restraints/Challenges
The high cost involved in gene therapy and unwanted immune responses will likely hamper the growth of the cancer gene therapy market's growth rate. The lack of healthcare infrastructure in developing economies will challenge the market.
This cancer gene therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cancer gene therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Cancer Gene Therapy Market
The development of vaccines used to treat COVID-19 is anticipated to make extensive use of gene and cell therapy technology. The treatment of coronavirus from the standpoint of RNA interference-based gene therapy offers a more direct method of battling viral genes in addition to conventional medications and vaccines, and is probably headed for a bright future.
Recent Development
- In June 2021, Eisai and Bristol Myers Squibb reached an agreement to work together on the creation and marketing of MORAb-202, Eisai's ADC for advanced solid tumours.
- In June 2021, EOS-448, an anti-TIGIT monoclonal antibody that had previously been approved in phase 1 for advanced solid malignancies, was created through a partnership between GSK and iTeos Therapeutics.
Global Cancer Gene Therapy Market Scope
The cancer gene therapy market is segmented on the basis of therapy and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapy
- Oncolytic Virotherapy
- Gene Induced Immunotherapy
- Gene Transfer
End User
- Hospitals
- Oncology Institutes
- Biotechnological Companies
- Clinical Research Laboratories
Cancer Gene Therapy Market Regional Analysis/Insights
The cancer gene therapy market is analysed and market size insights and trends are provided by country, therapy and end-user as referenced above.
The countries covered in the cancer gene therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the cancer gene therapy market due to the growing number of geriatric populations, well-established health-care infrastructures with specialized medical practitioners.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the increasing consumer awareness about cancer gene therapy, increasing government initiatives in propagating this treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Cancer Gene Therapy Market Share Analysis
The cancer gene therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cancer gene therapy market.
Some of the major players operating in the cancer gene therapy market are:
• Biogen (U.S.)
• Sarepta Therapeutics Inc. (U.S.)
• Gilead Sciences, Inc. (U.S.)
• Amgen, Inc. (U.S.)
• Novartis AG (Switzerland)
• Orchard Therapeutics Plc (U.K.)
• Spark Therapeutics, Inc. (U.S.)
• AGC Biologics (U.S.)
• Anges, Inc. (Japan)
• Bluebird Bio, Inc. (U.S.)
• Jazz Pharmaceuticals Inc. (Ireland)
• Dynavax Technologies (U.S.)
• Human Stem Cells Institute (Russia)
• Sibiono (China)
• Shanghai Sunway Biotech Co., Ltd. (China)
• Uniqure N.V. (Netherlands)
• Gensight Biologics (France)
• Celgene Corporation (U.S.)
• Cellectis (France)
SKU-